Effect of niacin on adipocyte leptin in hypercholesterolemic rabbits

Cardiovascular Pathology

Volumn 17, Issue 4, 2008, Pages 219-225

  Yang, Jun ^a   Zhao, Shui ping ^a   Li, Jing ^a   Dong, Shao zhuang ^a  

^a CENTRAL SOUTH UNIVERSITY   (China)

Author keywords

Adipocyte; CD36; Hypercholesterolemia; Leptin; Niacin; Peroxisome proliferator activated receptor (PPAR )

Indexed keywords

CD36 ANTIGEN; CHOLESTEROL; LEPTIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MESSENGER RNA; NICOTINIC ACID; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA;

ADIPOCYTE; ANIMAL EXPERIMENT; ARTICLE; CHOLESTEROL DIET; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; HYPERCHOLESTEROLEMIA; MALE; NONHUMAN; PRIORITY JOURNAL; RABBIT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA ANALYSIS; SUBCUTANEOUS FAT;

ADIPOCYTES; ADIPOSE TISSUE; ANIMALS; ANTIGENS, CD36; ANTILIPEMIC AGENTS; CELL CULTURE TECHNIQUES; CHOLESTEROL, DIETARY; CHOLESTEROL, LDL; DISEASE MODELS, ANIMAL; GENE EXPRESSION; HYPERLIPIDEMIAS; LEPTIN; MALE; NIACIN; PPAR GAMMA; RABBITS; RNA, MESSENGER;

EID: 47149112797     PISSN: 10548807     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.carpath.2007.09.005     Document Type: Article

References (35)

1. Libby P. Inflammation in atherosclerosis. Nature 420 (2002) 868-874
2. Rajala M., and Scherer P. Minireview: the adipocyte: at the crossroads of energy homeostasis, inflammation, and atherosclerosis. Endocrinology 144 (2003) 3765-3773
3. Blaschke F., Takata Y., Caglayan E., et al. Obesity, peroxisome proliferator-activated receptor, and atherosclerosis in type 2 diabetes. Arterioscler Thromb Vasc Biol 26 (2006) 28-40
4. Pelleymounter M., Cullen M., Baker M., et al. Effect of the obese gene product on body weight regulation in ob/ob mice. Science 269 (1995) 540-543
5. Halaas J., Gajiwala K., Maffei M., et al. Weight-reducing effects of the plasma protein encoded by the obese gene. Science 269 (1995) 543-546
6. Peelman F., Waelput W., Iserentant H., et al. Leptin: linking adipocyte metabolism with cardiovascular and autoimmune diseases. Prog Lipid Res 43 (2004) 283-301
7. Leyva F., Godsland I., Ghatei M., et al. Hyperleptinemia as a component of a metabolic syndrome of cardiovascular risk. Arterioscler Thromb Vasc Biol 18 (1998) 928-933
8. Soderberg S., Ahren B., Jansson J., et al. Leptin is associated with increased risk of myocardial infarction. J Intern Med 246 (1999) 409-418
9. Wallace A., McMahon A., Packard C., et al. Plasma leptin and the risk of cardiovascular disease in the West of Scotland Coronary Prevention Study (WOSCOPS). Circulation 104 (2001) 3052-3056
10. Kang S., Kwon H., Hong B., et al. Expression of leptin receptor (ob-R) in human atherosclerotic lesions: potential role in intimal neovascularization. Yonsei Med J 41 (2000) 68-75
11. Kjerrulf M., Berke Z., Aspegren A., et al. Reduced cholesterol accumulation by leptin deficient (ob/ob) mouse macrophage. Inflamm Res 55 (2006) 300-309
12. Bodary P., Westrick R., Wickenheiser K., et al. Effect of leptin on arterial thrombosis following vascular injury in mice. JAMA 287 (2002) 1706-1709
13. Plutzky J. Peroxisome proliferator-activated receptors in vascular biology and atherosclerosis: emerging insights for evolving paradigm. Curr Atheroscler Rep 2 (2000) 327-335
14. De Vos P., Lefebvre A., Miller S., et al. Thiazolidinediones repress ob gene expression in rodents via activation of peroxisome proliferator-activated receptor gamma. J Clin Invest 98 (1996) 1004-1009
15. Cabrero A., Cubero M., Llaverias G., et al. Leptin down-regulates peroxisome proliferator-activated receptor γ (PPARγ) mRNA levels in primary human monocyte-derived macrophages. Mol Cell Biochem 275 (2005) 173-179
16. Silverstein R., and Febbraio M. CD36 and atherosclerosis. Curr Opin Lipidol 11 (2000) 483-491
17. Nozaki S., Kashiwagi H., Yamashita S., et al. Reduced uptake of oxidized low density lipoprotein in monocyte-derived macrophages from CD36-deficient subjects. J Clin Invest 96 (1995) 1859-1865
18. Nagy L., Tontonoz P., Alvarez J., et al. Oxidized LDL regulates macrophage gene expression through ligand activation of PPAR gamma. Cell 93 (1998) 229-240
19. Westendorf T., Graessler J., and Kopprasch S. Hypochlorite-oxidized low-density lipoprotein upregulates CD36 and PPARγ mRNA expression and modulates SR-BI gene expression in murine macrophages. Mol Cell Biochem 277 (2005) 143-152
20. Mckenney J. New perspectives on the use of niacin in the treatment of lipid disorders. Arch Intern Med 164 (2004) 697-705
21. Miller M. Niacin as a component of combination therapy for dyslipidemia. Mayo Clin Proc 78 (2003) 735-742
22. Taylor A., Sullenberger L., Lee H., et al. Arterial biology for the investigation of the treatment effects of reducing cholesterol (ARBITER) 2: a double-blind, placebo-controlled study of extended-release niacin on atherosclerosis progression in secondary prevention patients treated with statins. Circulation 110 (2004) 3512-3517
23. Rubic T., Trottmann M., and Lorenz R. Stimulation of CD36 and the key effector of reverse cholesterol transport ATP-binding cassette A1 in monocytoid cells by niacin. Biochem Pharmacol 67 (2004) 411-419
24. Rodbell M. Effects of hormones on glucose metabolism and lipolysis. J Biol Chem 239 (1963) 375-380
25. Oda A., Taniguchi T., and Yokoyama M. Leptin stimulates rat aortic smooth muscle cell proliferation and migration. Kobe J Med Sci 47 (2001) 141-150
26. Parhami F., Tintut Y., Ballard A., et al. Leptin enhances the calcification of vascular cells: artery wall as a target of leptin. Circ Res 88 (2001) 954-960
27. Yamagishi S., Edelstein D., Du X., et al. Leptin induces mitochondrial superoxide production and monocyte chemoattractant protein-1 expression in aortic endothelial cells by increasing fatty acid oxidation via protein kinase A. J Biol Chem 276 (2001) 25096-25100
28. Schafer K., Halle M., Goeschen C., et al. Leptin promotes vascular remodeling and neointimal growth in mice. Arterioscler Thromb Vasc Biol 24 (2004) 112-117
29. Zhao S., and Zhang D. Atorvastatin reduces interleukin-6 plasma concentration and adipocyte secretion of hypercholesterolemic rabbits. Clin Chim Acta 336 (2003) 103-108
30. Zhao S., and Wu J. Fenofibrate reduces tumor necrosis factor-alpha serum concentration and adipocyte secretion of hypercholesterolemic rabbits. Clin Chim Acta 347 (2004) 145-150
31. Rosenson R. Antiatherothrombotic effects of nicotinic acid. Atherosclerosis 171 (2003) 87-96
32. Ganji S., Qin S., Liu Y., et al. Niacin inhibits LDL oxidation and redox-sensitive VCAM-1 and MCP-1 expression in human aortic endothelial cells. [abstract]. Arterioscler Thromb Vasc Biol 24 (2004) E-125
33. Grundy S., Vega G., McGovern M., et al. Efficacy, safety, and tolerability of once-daily niacin for the treatment of dyslipidemia associated with type 2 diabetes: results of the assessment of diabetes control and evaluation of the efficacy of niaspan trial. Arch Intern Med 162 (2002) 1568-1576
34. Kubota N., Terauchi Y., Miki H., et al. PPAR gamma mediates high-fat diet-induced adipocyte hypertrophy and insulin resistance. Mol Cell 4 (1999) 597-609
35. Unno Y., Sakai M., Sakamoto Y., et al. Advanced glycation end products-modified proteins and oxidized LDL mediate down-regulation of leptin in mouse adipocytes via CD36. Biochem Biophys Res Commun 325 (2004) 151-156